Egalet Corporation (NASDAQ:EGLT) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On March12, 2018, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its fourth quarter and fiscal year ended December31, 2017. A copy of that press release and the attached financial schedules are attached as Exhibit99.1 to this report and incorporated herein by reference.
The information included in this Item 2.02 (including Exhibit99.1) is being furnished to Item 2.02 and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.
Item 9.01 – Financial Statements and Exhibits.
Press Release, dated March12, 2018, announcing financial results for the fourth quarter and fiscal year ended December31, 2017.
Egalet Corp ExhibitEX-99.1 2 a18-7951_1ex99d1.htm EX-99.1 Exhibit 99.1 Egalet Reports Fourth Quarter and Full Year 2017 Financial Results 120 percent combined prescription growth 2017 over 2016 55 percent net product sales growth 2017 over 2016 Q4 2017 costs and expenses reduced 21 percent from Q3 2017 Company to host conference call today at 8:30 AM EDT Wayne,…To view the full exhibit click here About Egalet Corporation (NASDAQ:EGLT) Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.